Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Core Points - Novartis shareholders approved all proposed resolutions at the Annual General Meeting, with 1,554 shareholders present, representing approximately 59.15% of issued shares [1] - A dividend increase of 5.7% to CHF 3.70 per share was approved, marking the 29th consecutive increase and resulting in a dividend yield of 3.0% [2][8] - Giovanni Caforio was re-elected as Chair of the Board of Directors, and Charles Swanton was elected as a new member of the Board [3][8] - The proposal to cancel 77,602,358 shares was approved, reducing share capital by CHF 38,025,155.42 [5] - Shareholders approved the total maximum aggregate compensation for the Board of Directors and the Executive Committee for the upcoming periods [6][8] Summary by Category Dividend and Financials - The approved dividend increase to CHF 3.70 per share represents a 5.7% rise and a 3.0% yield, with payment scheduled for March 12, 2026 [2][8] Board of Directors - Giovanni Caforio was confirmed as Chair, and Charles Swanton was newly elected, while Daniel Hochstrasser did not stand for re-election [3][8] - All current members of the Compensation Committee were re-elected, with Elizabeth McNally joining as a new member [4] Share Capital - The cancellation of 77,602,358 shares was approved, leading to a reduction in share capital from CHF 1,035,086,714.83 to CHF 997,061,559.41 [5] Compensation Approvals - Shareholders approved the maximum aggregate compensation for the Board of Directors and the Executive Committee for the upcoming financial year, along with the 2025 Compensation Report [6][8]